Drug Type Synthetic peptide |
Synonyms DEBIO-0824, SHK-186 |
Target |
Mechanism Kv1.3 blockers(Voltage-gated potassium channel subunit Kv1.3 blockers), T lymphocytes modulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plaque psoriasis | Phase 1 | CA | 01 Oct 2014 | |
Autoimmune Diseases | Phase 1 | NL | - | - |
Inflammatory Bowel Diseases | Preclinical | US | - | - |
Lupus Nephritis | Preclinical | US | - | - |
Multiple Sclerosis | Preclinical | US | - | - |
Myositis, Inclusion Body | Preclinical | US | - | |
Obesity | Preclinical | US | - | |
Vasculitis | Preclinical | US | - | - |
Phase 1 | 24 | liodrllmkt(hxunvbfhor) = The most common adverse events were temporary mild (Grade 1) hypoesthesia (n = 20; 75% placebo, 85% dalazatide) and paresthesia (n = 15; 25% placebo, 70% dalazatide) involving the hands, feet, or perioral area. awljxkzuzg (lukbtccapt ) | Positive | 19 Jul 2017 | |||
Placebo |